Open AccessAdjuvant Rituximab Therapy of Pemphigus
Author(s) -
Luisa Lunardon,
Kathleen J. Tsai,
Kathleen J. Propert,
Nicole Fett,
John R. Stanley,
Victoria P. Werth,
Donald E. Tsai,
Aimee Payne
Publication year - 2012
Publication title -
archives of dermatology
Language(s) - English
Resource type - Journals
eISSN - 1538-3652
pISSN - 0003-987X
DOI - 10.1001/archdermatol.2012.1522
Subject(s) - medicine , rituximab , pemphigus , adjuvant , dermatology , adjuvant therapy , antibody therapy , immunology , antibody , chemotherapy , monoclonal antibody
We conducted a retrospective study of patients with pemphigus vulgaris (n = 24) and foliaceus (n = 7) treated with adjuvant rituximab to determine efficacy and adverse events. The end point for efficacy was complete remission of disease taking no or minimal therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom